Aspira Pathlab & Diagnostics Ltd (540788) — FY26 Annual Report | 1 September 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company dispatched letters to non-email shareholders with Annual Report access link.
💡 Investor Takeaway
Shareholders must update email addresses to receive future communications and access the Annual Report online.

Aspira Pathlab & Diagnostics announced that it dispatched letters to non-email shareholders on September 1, 2026, providing the web-link to access the Annual Report 2025-26, as required under SEBI Regulation 36(1)(b). The notice also confirmed the 53rd AGM scheduled for September 25, 2026, at 2:00 PM IST via video conference, and urged shareholders to update their email addresses to receive future communications.

📄 View Original Announcement (PDF)

About Aspira Pathlab & Diagnostics Ltd (540788)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹98.18 Cr P/E: 40.9 ROE: 33.2% ROCE: 28.4%

View full 540788 stock details →

📡 Get AI alerts when 540788 files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track 540788 — Free

📊 More 540788 filings

See all 540788 filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day